癌症干细胞（CSC）是导致癌症异质性的细胞类型之一。癌细胞停滞在G0期，并通过自我更新和多能性产生非CSC后代，导致肿瘤复发、转移和对化疗的抵抗。它们可以刺激肿瘤复发并使转移性肿瘤重新生长。因此，CSCs是根除肿瘤的一个有希望的目标，并且已经考虑开发抗CSCs疗法。近年来，竞争性内源 RNA (ceRNA) 已成为一类重要的转录后调节因子，通过竞争 microRNA (miRNA) 结合来影响基因表达。此外，异常的 ceRNA 表达与肿瘤进展相关。最近的研究结果表明，ceRNA 网络可以通过对 CSC 的影响导致肿瘤进展。为了克服 CSC 引起的治疗耐药性，我们需要加深对 ceRNA 与 CSC 相关复发机制的了解。因此，本综述旨在讨论 ceRNA 在 CSC 功能中的作用。靶向 ceRNA 可能会为新的癌症治疗靶点开辟道路，并可用于临床研究。© 2024 作者。

Cancer stem cells (CSCs) are one of the cell types that account for cancer heterogeneity. The cancer cells arrest in G0 and generate non-CSC progeny through self-renewal and pluripotency, resulting in tumor recurrence, metastasis, and resistance to chemotherapy. They can stimulate tumor relapse and re-grow a metastatic tumor. So, CSCs is a promising target for eradicating tumors, and developing an anti-CSCs therapy has been considered. In recent years competing endogenous RNA (ceRNA) has emerged as a significant class of post-transcriptional regulators that affect gene expression via competition for microRNA (miRNA) binding. Furthermore, aberrant ceRNA expression is associated with tumor progression. Recent findings show that ceRNA network can cause tumor progression through the effect on CSCs. To overcome therapeutic resistance due to CSCs, we need to improve our current understanding of the mechanisms by which ceRNAs are implicated in CSC-related relapse. Thus, this review was designed to discuss the role of ceRNAs in CSCs' function. Targeting ceRNAs may open the path for new cancer therapeutic targets and can be used in clinical research.© 2024 The Authors.